AstraZeneca (LON:AZN) had its price objective boosted by research analysts at Deutsche Bank from GBX 5,600 ($75.37) to GBX 5,700 ($76.72) in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank’s price objective indicates a potential upside of 21.17% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a report on Monday. Morgan Stanley reiterated an “equal weight” rating and set a GBX 5,000 ($67.29) price target on shares of AstraZeneca in a report on Friday, December 1st. J P Morgan Chase & Co set a GBX 4,800 ($64.60) price target on shares of AstraZeneca and gave the company a “neutral” rating in a report on Thursday, November 30th. Jefferies Group reiterated a “hold” rating and set a GBX 5,100 ($68.64) price target on shares of AstraZeneca in a report on Thursday, November 16th. Finally, HSBC upped their price target on shares of AstraZeneca from GBX 4,340 ($58.41) to GBX 4,380 ($58.95) and gave the company a “reduce” rating in a report on Thursday, November 16th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of GBX 5,169 ($69.57).

Shares of AstraZeneca (LON AZN) opened at GBX 4,704 ($63.31) on Tuesday. AstraZeneca has a 12-month low of GBX 3,996 ($53.78) and a 12-month high of GBX 5,520 ($74.29).

ILLEGAL ACTIVITY WARNING: “Deutsche Bank Increases AstraZeneca (AZN) Price Target to GBX 5,700” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/07/deutsche-bank-increases-astrazeneca-azn-price-target-to-gbx-5700.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.